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1. Page 2 - the modifications here are fairly minimalistic and the abbreviations ARTD2
and ARTD1 are not even defined.
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and ARTD1 are not even defined.
     In the corresponding section we incorporated the basic information on the newly
proposed nomenclature in our previous version upon the suggestion of the Reviewer.
We agree with the Reviewer that the appearance of the new nomenclature in our
manuscript is important. Moreover, in the current version we added ARTD-2 as a
keyword to help those future readers that follow the new nomenclature. The fact that
ARTD1 is the equivalent of PARP-1 is defined in the chapter “PARP superfamily”
second paragraph, first row. We added the abbreviation of ARDT-2 in the last sentence
in the first paragraph of the chapter “The PARP superfamily”. We think that these are
sufficient for the understanding of the position of PARP-2 in the PARP/ARTD
superfamily.
     We would like to note here, that the proposed new nomenclature did not gain
ground in the scientific community yet. There are only 3 relevant papers on Medline for
the keyword ARTD1, ARTD2 or ARTD (since 2010, the publication of the paper by
Hottiger et al. describing the new nomenclature). According to Medline there are
already around 290 papers published only in 2012 that contain the keyword PARP.
These data (290 vs. 3) clearly show that the PARP nomenclature is used mostly in the
literature. Moreover, even the authors of the new proposal themselves still use the old
nomenclature “PARP” (e.g. Erener S … Hottiger MO: Inflammasome-Activated
Caspase 7 Cleaves PARP1 to Enhance the Expression of a Subset of NF-κB Target
Genes. Mol Cell. 2012 Mar 28. [Epub ahead of print]), or Erener S … Hottiger MO
Poly(ADP-ribose)polymerase-1 (PARP1) controls adipogenic gene expression and
adipocyte function. Mol Endocrinol. 2012 Jan;26(1):79-86.).
     In summary, we are confident that our review sufficiently takes the new
nomenclature into consideration despite of the fact that it is not yet accepted by the
scientific community.
2. Page 3 line 12 - what is meant by "bear" mutations ? Do you mean that there is no
sequence homology?
Sequence homology modeling was carried out by Ame and co-workers (Ame et al.
Bioessays. 26:882-893. 2004). They classified sequences as PARPs on the basis of
sequence homology, therefore sequence homology does exist. However, mutation(s)
in a sequence does not necessarily mean that sequence homology is lost. In the
incriminated text, mutations mean rather point mutations that affect usually catalytic
amino acids. We had no intention to indicate the loss of sequence homology. To avoid
such misunderstanding, we exchanged “bear” to “carry”.
3. Page 3 line 34 - can more details of the alternative splicing be given and a
reference?
We drew our conclusions from the sequences available sequences at NCBI. Now we
stated the source of these data in the manuscript.
4. Page 6 line 27 - maybe "suggest" would be more appropriate than "indicate" . Is
there any evidence that PARP-2 has a similar role in humans? If not then this sentence
needs qualification to this effect (eg The results from these experimental models would
suggest that ??).
In agreement with the Reviewer we changed “indicate” to “suggest”.
Indeed, there is no human data available in that regard. To fulfill the demand of the
Reviewer we included the above proposed text.
5. Page 7 line 8 - what SNPs impact on PARP-2 function and how?
We thank for the Reviewer for this suggestion. We would like to point out that although
the SNPs were described but their actual mode of action is unknown. Nonetheless, we
included some possible explanations.
Powered by Editorial Manager® and Preprint Manager® from Aries Systems Corporation
Sakugawa and colleagues have shown on a cohort of 18 Japanese men that such
PARP-2 SNPs coincide with azoospermia in humans. Sakugawa and colleagues
identified five SNPs. Three of them fall into the coding region, while two into the 3’
UTR. The SNPs in the coding region are all in the catalytic domain. One is
synonymous (1159C/T), while two others (1359G/A and 1469A/C) lead to an amino
acid change: Arg/Gln and Asn/His, respectively. It is tempting to speculate that
changes in the catalytic domain may affect the catalytic activity of PARP-2. SNPs in the
3’UTR (1789A/C and 1790 T/C) may interfere with mRNA stability leading to the
reduction of PARP-2 mRNA copy number and consequently decreasing PARP-2
protein levels. Lower PARP-2 levels, or lower PARP-2 activity may interfere with
spermiogenesis as described in the respective chapter.
We have incorporated these data into the manuscript.
6. Page 7 line 51 in the revised sentence, should it read "A defect in PARP-2 in mouse
models?.
We narrowed the focus of our affirmation by adding “in murine models”.
7. Page 8 line 9 - please give model.
We specified the model in the given sentence.
8. Page 12 line 56 in the revised sentences: What evidence is there that PARP-1 and
PARP-2 ribosylate different substrates?
At the indicated site there is no suggestion that PARP-1 and PARP-2 would PARylate
different substrates.
9. Page 13 line 22 in the revised sentences: Would not the selective targeting of
PARP-2 mediated repair run the risk of increasing the complications in normal tissue
where radiation exposure doses might be lower?
The Reviewer is absolutely right, such phenomenon may take place. Based on the
comment of the Reviewer we feel that we drew too distant conclusions, therefore we
removed these sentences.
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Abstract 
Poly(ADP-ribose) polymerase (PARP)-2 is a nuclear enzyme that belongs to the PARP 
family and PARP-2 is responsible for 5-15% of total cellular PARP activity. PARP-2 was 
originally described in connection to DNA repair and in physiological and pathophysiological 
processes associated with genome maintenance (e.g. centromere and telomere protection, 
spermiogenesis, thymopoesis, azoospermia and tumorigenesis). Recent reports identified 
important rearrangements in gene expression upon the knockout of PARP-2. Such 
rearrangements heavily impact on inflammation and metabolism. Metabolic effects are 
mediated through modifying PPAR and SIRT1 function. Altered gene expression gives rise 
to a complex phenotype characterized primarily by enhanced mitochondrial activity that 
results both in beneficial (loss of fat, enhanced insulin sensitivity) and in disadvantageous 
(pancreatic beta cell hypofunction upon high fat feeding) consequences. Enhanced 
mitochondrial biogenesis provides protection in oxidative stress related diseases. Hereby, we 
review the recent developments in PARP-2 research with special attention to the involvement 
of PARP-2 in transcriptional and metabolic regulation. 
 
The PARP superfamily 
Poly(ADP-ribosyl)ation is a transient post-translational modification of proteins mediated 
by poly(ADP-ribose) polymerase (PARP) enzymes. This is a dynamic process during which 
the enzymes catalyze the formation of ADP-ribose polymers onto different acceptor proteins 
using NAD+ as a substrate. The half-life of the polymer is very short since it is quickly 
degraded by poly(ADP-ribose) glycohydrolase (PARG). PARPs constitute a family of 17 
members, encoded by 17 different genes sharing a conserved sequence coding for the 
catalytic domain that contains the PARP signature motif, a highly conserved sequence that 
forms the active site [1]. Based on sequence and structural homologies and the similarity of 
the reactions catalyzed, Hottiger and colleagues recently proposed to unite all ADP-ribose 
transferases (PARPs and mono-ADP-ribosyl transferases) in one protein family [2]. The 
same study proposed a new nomenclature for these enzymes, where PARP-2 was renamed 
ARTD2 (ADP-ribosyltransferase Diphtheria toxin-like 2). 
The prototypical enzyme of the PARP family is PARP-1 (ARTD1). PARP-1 cleaves NAD+ 
to ADP-ribose and nicotinamide followed by the attachment of the first ADP-ribose moiety to 
a glutamate or aspartate residue of target proteins. During the elongation of the polymer 
further ADP-ribose moieties are attached to these protein-bound monomers. In the absence 
of DNA damage the constitutive polymer levels are usually very low and appear as mono- or 
oligo(ADP-ribose). However, in response to DNA strand breaks the levels of poly(ADP-
ribose) (PAR) polymers increase 10-500-fold and large [3,4], branched PAR polymers occur 
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on different acceptor proteins and PARP-1 itself (auto-PARylation) (Fig. 1.). Upon extensive 
PARP-1 activation cellular NAD+ levels are markedly reduced [5]. Poly(ADP-rybosyl)ation, at 
any level, is likely to have important effects on the acceptor’s properties, hence PARylation 
and PARPs are involved in the regulation of various cellular processes [6]. In cells polymers 
can be detected as early as 2 to 3 minutes after the one-off induction of DNA damage, and 
then PAR polymers are quickly degraded by PARG. In tissues, PAR levels can be detected 
on a longer timeline as reflecting a steady state between synthesis and degradation. Some 
PARP enzymes carry mutations in the catalytic domain and hence are either inactive or 
perform only mono-, or oligo(ADP-ribosyl)ation [1,2,7]. 
 
The structure of the PARP-2 gene and PARP-2 protein 
PARP-2 was discovered when residual DNA-dependent PARP activity was detected in 
PARP-1-/- murine embryonic fibroblasts (MEFs) [8]. So far PARP-1, PARP-2 and PARP-3 are 
the only PARP enzymes whose catalytic activity is stimulated by DNA strand breaks 
suggesting that they function as crucial members in the cellular pathways responding to DNA 
damage [8-11]. 
PARP-2 gene is located on chromosome 14 in humans. The gene is driven by a 
bidirectional promoter that PARP-2 shares with RNase P [12]. Such combination of RNA 
polymerase II and RNA polymerase III genes is relatively rare. A functional TATA box and 
DSE/Oct-1 expression control elements were identified in the promoter regulating PARP-2 
expression [12]. Due to alternative splicing, two isoforms of PARP-2 exist with the longer 
isoform containing an extra set of 13 amino acids on the border between the DNA binding 
domain and domain E. The longer isoform has been identified, or predicted in humans [13], 
common chimpanzee (Pan troglodytes) [14], northern white-cheeked gibbon (Nomascus 
leucogenys) [15] and sumatran orangutan (Pongo abelii) [16] according to the NCBI 
database. The sequences of different mammalian PARP-2 genes are highly homologous 
(Fig. 2.). Although PARP-2 is absent in birds, sequences similar to PARP-2 can be found in 
lower vertebrates (Danio rerio, Xenopus), lower animals (e.g. sponges) and in Arabidopsis 
thaliana [17]. 
The tissue-specific expression of PARP-2 was primarily characterized by in situ 
hybridization. Liver expression of PARP-2 was high at fetal age 12.5 days, decreased at 18.5 
days fetal age and was even lower in newborn mice [8,18]. In adult mice the expression of 
PARP-2 is low in the liver (the lowest among the metabolic tissues; Bai P, unpublished data). 
It is tempting to speculate that the gradual decrease in PARP-2 expression by age during 
fetal and postnatal development points toward the possible involvement of PARP-2 in early 
stage hemopoiesis that takes place in the liver.  
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In the central nervous system PARP-2 content was high in the spinal ganglia and in 
certain parts of the brain. In the neocortical areas PARP-2 expression is elevated as 
compared to lower brain regions. High PARP-2 expression was detected in stratum 
granulosum of the dentate gyrus and the stratum pyramidale of the hippocampus and was 
even higher in the cortex and the olfactory bulb [18]. Apart from the previously mentioned 
tissues, PARP-2 is highly expressed in the cortical region of the kidneys, the spleen, adrenal 
glands, stomach, thymus and intestinal epithelium [18]. The testis was also positive for 
PARP-2 expression. 
In humans a slightly different expression pattern was detected. PARP-2 was very 
abundant in the skeletal muscle, brain, heart, testis, it was high in pancreas, kidney, 
placenta, ovary, spleen and low PARP-2 expression was detected in the lungs, leukocytes, 
gastrointestinal tract (both colon and small intestine), thymus and liver [19]. 
Translation of the PARP-2 mRNA yields a protein product of 62 kDa apparent molecular 
weight. PARP-2 protein can be divided into similar functional regions as PARP-1: The N-
terminus of mouse PARP-2 contains the DNA binding domain (DBD), followed by domain E 
and the catalytic domain (domain F) [8]. The DBD is formed by a SAP domain that is 
responsible for DNA binding [20], and contains a functional nuclear localization signal (NLS) 
[21] and a nucleolar localization signal (NoLS) [22]. A caspase-3 cleavage site defines the 
border between the DBD and domain E, which is homologous to the caspase-3 site in the E 
domain of PARP-1 [23]. Domain E serves as a homodimerization interface, an 
automodification domain and a protein-protein interaction domain as well [24]. Auto-
poly(ADP-ribosyl)ation of PARP-2 takes place on domain E [25] and on lysine 36 and 37 that 
are targets of simultaneous acetylation [26,27]. The PARP-2 interactome was mapped by 
Isabelle and co-workers [28], who identified a large number of proteins. These proteins 
covered a wide array of functions such as cell cycle, cell death, DNA repair, DNA replication, 
transcription, metabolism, energy homeostasis and RNA metabolism. 
Domain F on the C-terminus of PARP-2 harbours the PARP signature motif carrying the 
essential amino acid residues for catalysis [8]. Domain F is separated from domain E by a 
caspase-8 cleavage site [29]. PARP-2 and PARP-1 share a catalytic domain of 69% 
similarity, with the exception that PARP-2 contains an additional three amino acid insertion in 
the loop connecting the β-strands k and l in PARP-1 [8,30,31] (Fig. 3.). The three 
dimensional structure of the catalytic domain also shows high similarity, however the catalytic 
domain of PARP-2 has a narrower catalytic cleft that likely explains the lower substrate 
affinity and turnover rate of PARP-2 as compared to PARP-1 (KM for NAD
+ 50/130 M; 
kcat/KM 6000 s
-1 M-1/323 s-1 M-1 for PARP-1/-2 respectively) [8,30]. PARP-2 accounts for 5-
15% of total PARP activity in cells depending on the model used [8,32,33]. PARP-2 performs 
auto [18] and hetero-PARylation of proteins. Troiani and co-workers have identified possible 
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targets of PARP-2 activity that covered proteins involved in transcription, translation and 
mitochondrial organization [34]. 
 
PARP-2 in the maintenance of genomic integrity 
PARP-2 in DNA repair and genomic integrity 
PARP-1 is a well established DNA-repair protein [6], therefore the functional similarity 
with PARP-2 suggested a role for PARP-2 in the maintenance of DNA integrity. Upon the 
induction of DNA damage (ionizing irradiation, or laser irradiation), PARP-2 accumulates at 
the damage foci [35] with a slower kinetics  than PARP-1, and PARP-2 persisted longer at 
DNA damage sites [36]. In murine embryonic fibroblasts (MEFs) the loss of PARP-2 leads to 
hypersensitivity to ionizing irradiation and cell cycle arrest in G1 [23], although PARP-2-/- cells 
are less sensitive to ionizing radiation than PARP-1-/- cells [23,24]. In line with these 
observations female lethality due to X chromosome instability was observed in PARP-1+/- 
PARP-2-/- mice [23]. 
PARP-2 preferentially binds to one nucleotide gaps [25] and it is involved in single strand 
repair processes. As shown in murine models, upon the loss of PARP-2, base excision repair 
(BER) slows down [18]. Moreover, PARP-2 interacts with numerous members of the BER 
machinery such as XRCC1, PARP-1, DNA pol and DNA ligase III [18] that further signifies 
its importance in BER. It is tempting to hypothesize that the early embryonic lethality of the 
PARP-1/PARP-2 double knockout mice [23] might be due to the strong impairment of DNA 
repair processes.  
PARP-1 has been described to participate in double strand break repair [37]. Nicolás and 
co-workers have identified the accumulation of double strand breaks in PARP-2-/- murine 
thymocytes [38]. This observation is in line with previous report by Yelamos and colleagues 
[24] who suggested that PARP-2 interacts with the Ku proteins, mediators of double strand 
break repair. Moreover, Robert and colleagues have identified PARP-2 as a suppressor of 
recombination during immunoglobulin class switch events in murine and human B cells [39], 
while Bryant et al. have suggested that both PARP-1 and -2 are essential in resolving 
blocked replication forks by homologous recombination in CHO and murine embryonic 
fibroblasts (MEFs) [37,40]. The fact that the ATM/PARP-2 double knockout genotype is 
embryonic lethal [20] further supports the involvement of PARP-2 in double strand break 
repair during replication. Moreover, the fact that mitomycin C treatment that leads to DNA 
double strand breakage provoked the induction of PARP-2 expression and other double 
strand break repair proteins in human cervical carcinoma cells also underlines the 
involvement of PARP-2 in double strand break repair [41]. 
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Appropriate telomere and centromere maintenance requires PARP-2. PARP-2 binds to 
and negatively regulates the DNA binding of telomere-binding protein, TRF-2 in different 
rodent and human cell models. The loss of PARP-2 expression increased the frequency of 
spontaneous chromosome and chromatid breaks and the number of DNA ends lacking 
detectable telomere repeats [42].  
PARP-2 localizes to centromeres in human and murine cells in a cell-cycle dependent 
manner and interacts with the kinetochore proteins centromere protein A (CENPA), 
centromere protein B (CENPB) and mitotic spindle checkpoint protein BUB3 in 
prometaphase and metaphase [43]. Interestingly, this centromeric accumulation of PARP-2 
is increased when microtubule dynamics are disrupted suggesting a dominant role of PARP-
2 in accurate chromosome segregation [44]. 
Incomplete or insufficient DNA repair may ultimately lead to either cell death, or cellular 
transformation and tumorigenesis. PARP-1 has been associated with both cell death [45] and 
tumorigenesis [46]. PARP-2 seems to be involved in cell death regulation similarly to PARP-1 
[44,47]. However, Cohausz and colleagues have found differences in the expression of cell 
death genes upon N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment in PARP-1 and -2 
knockdown cells. Furthermore, PARP-2 is also engaged in tumorigenesis. In mice the double 
deletion of PARP-2 and p53 induced spontaneous lymphomas and certain sarcomas [38] 
and decreased expression of PARP-2 correlated with increased susceptibility to alkylator-
induced acute myeloid leukemia (AML) [48]. Results from these experimental models 
suggest that PARP-2 has a dominant role in suppressing leukemias [49]. 
 
Role of PARP-2 in chromatin remodeling and genome maintenance during 
spermiogenesis 
PARP-2 is expressed in the testis of mice [18] and rats [50], and is highly expressed in 
human testis [19]. Moreover, PARP-2 is found in the ejaculated spermatozoa in both mice 
and in humans [44,51]. However, PARP-2 seems to be responsible for a smaller portion of 
PARP activity than PARP-1 in rat testis [52]. These observations prompted the study of the 
possible testicular functions of PARP-2 in mice. Dantzer and co-workers have revealed that 
upon crossing of PARP-2-/- males and females litter size was lower then in colonies bred by 
crossing wild type mice. A smaller testis size and high number of abnormal spermatids in the 
distal epidymis have also been reported [44].  
Decreased spermatogenesis is likely to have multiple roots that all trace back to 
insufficient maintenance of genomic integrity during spermatocyte differentiation. The 
differentiation of spermatozoa was found to be hampered and large numbers of apoptotic 
cells were detected in murine testis [44]. Cell death is probably linked to hampered meiotic 
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sex chromosome inactivation, and the block of cell division in meiosis I, whereby 
chromosome missegregation was detected [44]. Jha and colleagues, based on studies on 18 
healthy and 12 infertile humans, also proposed a role for PARP-2 in the preservation of 
genomic integrity by protecting DNA against oxidative stress [53]. Spermiogenesis involves 
the compaction of DNA and the exchange of histones to different protamines [54]. In this 
process PARP-2 (and PARP-1) regulate the activity of topoisomerase II that is essential for 
appropriate DNA organization (e.g. removal of histone 1) [55], transition protein 2 (TP2) and 
the transition chaperone HSPA2 [56] as shown in mice. 
Different SNPs impacting on PARP-2 functionality may also hamper human 
spermiogenesis. Sakugawa and colleagues [51] have shown on a cohort of 18 Japanese 
men that such PARP-2 SNPs coincide with azoospermia in humans. Sakugawa and 
colleagues identified five SNPs. Three of them fall into the coding region, while two into the 3’ 
UTR. The SNPs in the coding region are all in the catalytic domain. One is synonymous 
(1159C/T), while two others (1359G/A and 1469A/C) lead to an amino acid change: Arg/Gln 
and Asn/His, respectively. It is tempting to speculate that changes in the catalytic domain 
may affect the catalytic activity of PARP-2. SNPs in the 3’UTR (1789A/C and 1790 T/C) may 
interfere with mRNA stability leading to the reduction of PARP-2 mRNA copy number and 
consequently decreasing PARP-2 protein levels. Lower PARP-2 levels, or lower PARP-2 
activity may interfere with spermiogenesis as described above. 
 
 
The role of PARP-2 in thymopoesis and inflammatory regulation 
The earliest reports on PARP-2 described high PARP-2 expression in the subcapsular 
zone of the thymus where lymphocyte proliferation is the most intense. PARP-2 expression 
gradually decreases towards the center of the thymus as lymphocytes differentiate and 
mature [18,47]. PARP-2 transcripts were detected in the white pulp of the spleen and Peyer 
patches in mice which also points toward the involvement of PARP-2 in the proliferation of 
lymphocytes [18]. 
In line with these observations, the deletion of PARP-2 in mice led to decreases in the 
weight of thymus and in the total cell numbers and number of CD4+, CD8+ thymocytes in 
thymus [47]. The loss of the double positive thymocytes was due to enhanced p53-mediated 
apoptosis [47]. Increased expression of a pro-apoptotic, bcl-2 homolog NOXA showed 
correlation with the enhanced apoptosis [47]. Apoptosis can be reversed by the removal of 
p53 [38] suggesting that cell death is induced by unresolved DNA damage. In line with this 
observation, when PARP-2-/- mice were bred on a p53-/- background, spontaneous 
lymphomas and to a smaller extent other sarcomas developed in the double knockout mice 
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[38] indicating a functional interplay between these two proteins in protecting genome 
integrity. 
It remains to be seen whether atrophy of thymus and the higher rate of thymocyte 
apoptosis in PARP-2-/- mice results in a restricted T cell repertoire and altered T cell 
responses. In fact, PARP inhibition or PARP-1 depletion has provided marked protection in 
most animal models of inflammation with many of them being dependent on T cell functions 
[45,57]. The defect of PARP-2 seems to be associated with a narrower spectrum of diseases 
in murine models. The lack of PARP-2 impairs astrocyte activation [58] and provides 
protection against colitis [59], while it has no effect in models of contact hypersensitivity [60], 
irritative dermatitis [60] or pancreatitis [61]. Interestingly, a common set of genes (iNOS, Il-
1, TNF) has been shown to be regulated by both PARP-1 and PARP-2 suggesting similar 
or overlapping mechanisms in inflammatory regulation by the two PARP isoforms. However, 
yet the exact mechanism of protection by genetic PARP-2 deletion is unknown [58,59]. 
 
PARP-2 in the regulation of gene expression 
Recent reports revealed that the depletion of PARP-2 modifies the activity of multiple 
transcription factors [62-64]. In HepG2 cells depleted of PARP-2 by shRNA, we have found 
the dysregulation of more than 600 genes in microarray experiments (Szántó and Bai, 
unpublished data) indicating an important role for PARP-2 in the regulation of gene 
expression. 
PARP-2 acts at multiple levels on gene transcription. PARP-2 might be capable of 
modifying chromatin through regulating transcriptional intermediary factor (TIF)-1 and 
heterochromatin protein (HP)-1 [65]: depletion of PARP-2 modified the expression of two 
genes (Mest and HNF4) that are dependent on the TIF1-HP1 complex [65]. Poly(ADP-
ribosyl)ation and PARP-1 have eminent roles in epigenetic control [66-69]. Based on the 
similarities of PARP- and PARP-2-catalyzed reactions, and partially overlapping interactome 
and acceptor protein profile, it is tempting to assume that similar epigenetic roles may also 
be assigned to PARP-2. 
PARP-2 can influence gene expression through more direct interactions. PARP-2 
interacts with topoisomerase I and topoismerase II [40,55] and may thus regulate the 
rearrangement of DNA structure in conjunction with RNA transcription. Moreover, PARP-2 
has been shown to interact with nucleophosmin/B23 [22] that is involved in rRNA 
transcription [70]. RNA polymerase I inhibition removes PARP-2 from the nucleolus, however 
the deletion of PARP-2 does not change rRNA expression. Thus the exact mechanism 
whereby PARP-2 regulates rRNA expression requires further investigation. On the course of 
mRNA expression, also known as RNA polymerase II-mediated transcription, PARP-2 can 
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act as either a positive co-factor, or a repressor of gene expression. Transcription factors 
regulated by PARP-2 are summarized in Table 1. 
 
Nuclear receptor signaling 
PARP-2 has been shown to interact with several members of the nuclear receptor 
superfamily such as the peroxisome proliferator activated receptors (PPARs) and estrogen 
receptor (ER). 
The group of PPARs has three members, PPAR, PPAR and PPAR [71] that 
heterodimerize with the retinoid X receptor (RXR) and thus bind to DNA [72,73]. PPARs bind 
different lipophylic ligands [74]  that regulate their transcriptional activity. PPARs control the 
expression of a large set of genes involved in the regulation of energy, lipid and glucose 
homeostasis [75]. The binding of ligands to the receptors leads to receptor activation and the 
release of corepressor proteins and the subsequent binding of activators [76]. PARP-1 has 
been suggested to be involved in nuclear receptor function. Ju and colleagues [77] have 
shown that upon estrogen receptor activation, topoisomerase II creates DNA strand breaks 
that are resolved through the action of PARP-1. Moreover, inhibition of topoisomerase II or 
PARP-1 hampered efficient gene expression [77]. 
PARP-2 serves as a cofactor for the members of the PPAR transcription factor family. 
The absence of PARP-2 impairs PPAR activation but enhances PPAR and PPAR 
activation [63]. PARP-2 binds to PPAR-driven promoters and its absence decreases the 
expression of genes such as adipocytes protein 2 (aP2), CD36, lipoprotein lipase (LPL) and 
fatty acid synthase (FAS) [63]. Since PARP-2 is a DNA repair protein and can interact with 
topoisomerase II [55], it is possible that PARP-2 may also play a role in resealing 
transcription-related DNA breaks. The effects of PARP-2 depletion on PPAR and PPAR 
activation were demonstrated only in reporter assays [63], therefore further molecular and in 
vivo verification of these interactions is necessary. 
Estrogen receptor (ER) activation is repressed by the depletion of PARP-2 in luciferase 
reporter assays (P. Bai, unpublished data). The effect of PARP-2 on PPAR and ER may 
share similar molecular characteristics. Further investigation is required to reveal possible 
physiological consequences of the reduced ER activity upon PARP-2 ablation. It is 
important to note that PARP-2 does not interfere with the activation of ER, therefore ER 
and its target genes (e.g. keratin 19) are ideal negative controls in studies addressing the 
role of PARP-2 in nuclear receptor-mediated gene expression [63]. 
 
Interaction with SIRT1  
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SIRT1 belongs to the family of sirtuins. Sirtuins have seven homologs in humans and 
mice (SIRT1-7) [78,79]. SIRT1 is considered to be a nuclear enzyme [80], although it may 
also appear in the cytosol [81]. SIRT1 is an NAD+-dependent protein deacetylase [82] that 
enables SIRT1 to sense the energetic status of cells (e.g. changes in NAD+/NADH ratio) [83]. 
SIRT1 is activated by increases in NAD+ levels, or indirectly by different small molecule 
activators such as resveratrol [84], SIRT1720 [85], AMPK activators [86] or PARP inhibitors 
[87]. SIRT1 activation leads to the deacetylation and activation of numerous metabolic 
transcription factors such as PPAR gamma coactivator (PGC)-1 [88], FOXOs [89] and p53 
[90]. Their activation leads to increased mitochondrial biogenesis and oxidative metabolism 
through enhancing the expression of key mitochondrial enzymes involved in terminal 
oxidation, fatty acid degradation, and mitochondrial uncoupling in several target tissues 
[88,91]. 
It has been shown that PARP-2 can directly regulate the expression of SIRT1 [62]. 
PARP-2 serves as a negative regulator of SIRT1 expression, as the absence of PARP-2 
induces SIRT1 expression and results in higher SIRT1 activity [33,62]. PARP-2 binds to the 
murine SIRT1 promoter in a region between -1 - -91,  which is a highly conserved region 
among mammals, showing homology even in Xenopus [62]. It must be noted that the 
ablation, or pharmacological inhibition of PARP-1 also induces SIRT1 activity. However 
SIRT1 activation in the absence of PARP-1 depends on enhanced NAD+ availability and the 
ablation of PARP-1 does not alter the activity of the SIRT1 promoter [87]. 
SIRT1 induction upon PARP-2 ablation causes the deacetylation of PGC-1 and FOXO1, 
which in turn boost mitochondrial biogenesis by enhancing the expression of PGC-1, 
uncoupling protein (UCP)-2, muscle isoform of carnitine O-palmitoyltransferase 1 (mCPT1b), 
acyl coenzyme A oxidase I (ACOX1), medium-chain specific acyl-CoA dehydrogenase 
(MCAD), malonyl-CoA decarboxylase (MCD), Ndufa2, cytochrome c (cyt c) and COX IV [62]. 
The action of PARP-2 has been shown in multiple organs and tissues such as skeletal 
muscle, liver, smooth muscle [33,62] and an unexpected diadvantageous effect has been 
shown in the pancreas [62]. The depletion of PARP-2 was found not to interfere with SIRT2 
or SIRT3 activation [62]. 
Similar to PARP-2 gene inactivation, SIRT1 activation has been shown to inhibit the 
production of inflammatory mediators and suppress certain forms of inflammation [92-94]. It 
is therefore plausible that the induction of SIRT1 may be responsible for the antiinflammatory 
effect of PARP-2 depletion in colitis [59] and in astrocyte activation [58] . 
 
Thyroid transcription factor-1 
Nkx-2 transcription factors constitute a family of homeodomain-containing transcription 
factors. Thyroid transcription factor (TTF)-1 belongs to the Nkx-2 family and TTF-1 plays a 
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dominant role in lung morphogenesis, respiratory epithelial cell morphogenesis and 
differentiation [95,96]. In cultured lung epithelial cells PARP-2 interacts with TTF1 [64]. By 
affecting TTF1 activity PARP-2 may regulate the expression of surfactant protein-B. 
 
The role of PARP-2 in metabolic regulation 
Alterations in gene expression accompany various biological phenomena ranging from 
inflammatory responses (NOXA, TNF, IL-1, etc.) to metabolic regulation. The 
transcriptional regulatory role of PARP-2 has been linked to cellular metabolism. PARP-2-/- 
mice are smaller and leaner as they have less body fat than their wild type littermates 
[62,63]. At the same time PARP-2-/- mice showed higher oxygen consumption rates and 
lower respiratory quotient during the active (dark) phase which points toward higher fatty acid 
oxidation [62]. 
When examining the skeletal muscle of PARP-2-/- mice, increased mitochondrial content 
was observed in line with higher expression of genes related to oxidative metabolism and 
fatty acid oxidation which is in line with the above described phenotype [62]. The increase in 
oxidative metabolism can be explained by higher SIRT1 expression due the loss of the 
transcriptional repressor activity of PARP-2. It is the increase in SIRT1 expression that 
induces mitochondrial biogenesis through PGC-1 and FOXO1 deacetylation [62]. 
The liver of the PARP-2-/- mice displayed characteristics similar to the ones in skeletal 
muscle: SIRT1 induction and consequently enhanced mitochondrial biogenesis and oxidative 
metabolism [62]. Interestingly, the brown adipose tissue was not involved in the development 
of the energy expenditure phenotype in contrast to PARP-1-/- mice [62,87] 
The increased energy expenditure fuelled by enhanced mitochondrial biogenesis in 
skeletal muscle and liver had beneficial effects on the metabolism of PARP-2-/- mice. PARP-
2-/- mice are protected against diet-induced obesity, and insulin resistance of the animals was 
retained even after high fat feeding [62]. Interestingly, PARP-2-/- mice proved to be glucose 
intolerant after high fat feeding [62]. The pancreas in PARP-2-/- mice failed to appropriately 
respond to diet-induced insulin resistance as it showed no signs of hyperproliferation or 
reduction in pancreas weight, islet size and pancreatic insulin content [62]. Reduced 
expression of pancreatic and duodenal homeobox 1 (pdx-1) is likely to be responsible for the 
pancreatic hypofunction in PARP-2-/- mice [62]. 
Functions of the white adipose tissue (WAT) are orchestrated by the RXR/PPAR 
receptor [72]. We have shown that PARP-2 acts a cofactor of the RXR/PPAR dimer [63,97]. 
The loss of PARP-2 hampers RXR/PPAR receptor activation and decreases the expression 
of certain PPAR-driven genes (e.g. LPL, CD36, etc.). Due to that alterations in gene 
expression, the WAT of PARP-2-/- mice turned hypomorphic and hypofunctional [63]. 
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Moreover, in cellular models of adipocyte differentiation, the lack of PARP-2 resulted in 
decreased adipocytic differentiation [63]. It is of note that SIRT1 induction may inhibit PPAR 
[98] that may provide an auxiliary mechanism underlying WAT hypofunction in the absence 
of PARP-2. 
 
PARP-2 in oxidative stress-related diseases  
PARP-1 depletion, or pharmacological PARP inhibition is protective against numerous 
oxidative stress-related diseases [45]. Depletion of PARP-2 also resulted in a protective 
phenotype against diseases associated with increased oxidative stress. Genetic deletion or 
silencing of PARP-2 has provided protection in models of focal and global cerebral ischaemia 
[99,100], colitis [59] and doxorubicin-induced vascular smooth muscle damage [33]. Since 
PARP-2 accounts for a small fraction of total cellular PARP activity [8,32,33], it is unlikely that 
the ablation of PARP-2 could protect against the loss of cellular NAD+ and ATP suggesting 
different mechanisms of cell death as compared to the case of PARP-1 ablation. 
Cerebral ischaemia and doxorubicin-induced vascular impairment involve mitochondrial 
damage [101,102] and preventing mitochondrial damage proved to be a successful novel 
treatment in these pathologies [103-108]. Since SIRT1 has been demonstrated to enhance 
or restore mitochondrial activity in various tissues [62,87,91,109-111] it is logical to assume 
that the interference between PARP-2 and SIRT1 expression [62] could be key for the 
protective phenotype. Indeed, in the case of doxorubicin-induced vascular damage, 
enhanced SIRT1 expression and consequent stabilization of the mitochondrial membrane 
potential was proposed to be responsible for the protection provided by the PARP-2-/- 
phenotype [33] which might be a prototypical mechanism by which PARP-2 mediates 
oxidative stress-related pathologies. Moreover, ablation of PARP-2 led to the mitochondrial 
retention of apoptosis inducing factor (AIF) [100]. AIF is a mitochondrial protein that shuttles 
to the nucleus upon oxidative stress-evoked cell death in a PARP-1-dependent manner 
[112]. In a model of focal cerebral ischemia, ablation of PARP-2 only slightly reduced PAR 
formation but markedly inhibited the nuclear translocation of AIF [100]. This interesting 
finding may also be linked to the stabilization of mitochondrial membrane upon SIRT1 
induction. 
The involvement of PARP-2 in oxidative stress-related pathologies points towards the 
applicability and hence the development of PARP-2 specific inhibitors. However, all known 
PARP inhibitors are capable of inhibiting both PARP-1 and -2, which is not surprising since 
the catalytic domain of the enzymes are very similar and most PARP inhibitors bind there 
[30,31]. In the quest for synthesizing PARP-2 specific inhibitors, the laboratory of Gilbert de 
Murcia suggested the targeting of a loop that is unique in PARP-2, [25,30]. Efforts to develop 
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highly PARP-2-selective compounds have given rise to inhibitors that have 10-60 fold higher 
affinity for PARP-2 as compared to PARP-1 [113-117]. One of these inhibitors, UPF-1069 
that has 60 fold higher affinity towards PARP-2 than PARP-1, was shown to provide 
protection against cerebral ischemia [117]. Although at the moment such selectivity is the 
highest achievable, it is possible that in cellular models or in in vivo settings these inhibitors 
may partially inhibit PARP-1 too. Nevertheless, the development of highly PARP-2 specific 
inhibitors is of current interest. Since PARP-2 is a minor PARP isoform, its inhibition is an 
attractive way to counteract certain drawbacks of pan-PARP inhibition or PARP-1 specific 
inhibitors. Since PARP-2 accounts for only 5-15% of PARP activity [8,18,32,33] therefore it is 
tempting to speculate that its loss probably would not drastically hamper PARylation-
dependent DNA repair. Thus highly PARP-2 specific inhibitors may provide a preferable 
alternative for the treatment of metabolic diseases, whereas pan-PARP inhibitors may be 
superior in severe oxidative injury. However DNA damage assessment in such cases is an 
absolute necessity. 
 
Conclusions and perspectives 
PARP-2 has been shown to participate in multiple cellular processes such as DNA repair, 
maintenance of genomic integrity, spermiogenesis and thymopoesis. On the other hand, 
PARP-2 is involved in transcriptional regulation of metabolism and oxidative stress response. 
In fact, this plethora of functions partly overlaps with the functions of PARP-1 [24]. A better 
understanding of the similarities and differences between the actions of PARP-1 and -2 is of 
outmost importance. On the one hand PARP-1 and -2 can act synergistically, while on the 
other hand isoform specific functions of the PARP enzymes also exist. Specific targeting of 
PARP-2 may help overcome unwanted side effects of pan-PARP inhibition. 
Understanding the role of PARP-2 in DNA repair may hold importance in tumor biology. 
The better understanding of the role of PARP-2 in DNA repair may provide new knowledge 
on tumorigenesis, and can be capitalized in inducing synthetic lethality by joint inhibition of 
parallel DNA repair pathways [49].  
The metabolic effects of PARP-2 can be exploited in multiple different manners. 
Obviously, the depletion of PARP-2 can be utilized in combating metabolic diseases and 
mitochondrial stabilization may overcome oxidative stress-evoked damage. Better 
understanding the properties of PARP-2 may in turn facilitate the development of PARP-2 
specific inhibitors that may have advantages over pan-PARP inhibitors. 
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Figure legends 
 
Figure 1. The poly(ADP-ribosyl)ation cycle. 
NAM- nicotinamide, ADPR- ADP-ribose, PAR- poly(ADP-ribose), all other abbreviations are 
in the text. 
 
Figure 2. The structure of PARP-2 gene and PARP-2 protein. 
The PARP-2 gene is driven by a bidirectional promoter and consists of 16 exons. The protein 
product of the gene can be divided into three domains: DBD, domain E, domain F. Numbers 
bellow the protein product indicate amino acids on the border between domains. The arrows 
point at caspases-3 and caspases-8 cleavage sites. The highlighted amino acid sequence is 
the conserved 13 amino acid sequence of the longer PARP-2 isoform. 
18 mammalian PARP-2 sequences of the shorter isoform (Ailuropoda melanoleuca [118], 
Bos taurus [119], Callithrix jacchus [120], Canis lupus familiaris [121], Cavia porcellus [122], 
Cricetulus griseus [123], Equus caballus [124], Homo sapiens [13], Loxodonta africana [125], 
Macaca mulatta [126], Monodelphis domestica [127], Mus musculus [128], Nomascus 
leucogenys [15], Oryctolagus cuniculus [129], Pan troglodytes [14], Pongo abelii [16], Rattus 
norvegicus [130], Sus scrofa [131]) were compared in the Clustal W2 software 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and relative conservation of the amino acids 
were plotted. Higher values indicate higher levels of conservation. 
DBD- DNA binding domain, AM- automodification, NLS- nuclear localization signal, NoLS- 
nucleolar localization signal, SAP- SAP domain 
 
Figure 3. The three dimensional structure of the catalytic domain of PARP-1 and 
PARP-2. 
Crystal structure of PARP-1 (3GN7) and PARP-2 (3KJD) were retrieved from the protein data 
bank (PDB, www.rcsb.org). Both structures contain an inhibitor (in color), the PARP-1 
catalytic domain is in complex with A861696, while the PARP-2 catalytic domain is in 
complex with ABT-888 [31]. The catalytic cleft and the PARP-2 specific loop is indicated. 
 
Figure 4. Tissue specific functions of PARP-2. 
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Table 1. Transcription factors directly regulated by PARP-2. 
Name Mode of action Effects Model sytem Known tissue 
specificity 
Ref 
ER Unknown Depletion of PARP-2 suppress ER 
activation. 
Luciferase reporter system in PARP-2 
specific shRNS treated HEK293T cells. 
unknown - 
RXR/PPAR Unknown Depletion of PARP-2 enhance PPAR 
activation. 
Luciferase reporter system in PARP-2 
specific shRNS treated HEK293T cells. 
Unknown [59] 
RXR/PPAR Unknown Depletion of PARP-2 enhance PPAR 
activation. 
Luciferase reporter HEK293T in PARP-
2 specific shRNS treated HEK293T 
cells. 
Unknown [59] 
RXR/PPAR Cofactor of 
receptor 
Modulates transcription of PPARtarget 
genes, 
Depletion of PARP-2 leads to WAT 
hypofunction. 
Luciferase reporter system in PARP-2 
specific shRNS treated HEK293T cells; 
PARP-2 knockout mice; embryonic 
fibroblasts from PARP-2 knockout mice. 
White adipose tissue [59] 
SIRT1 Transcriptional 
repressor of the 
SIRT1 promoter. 
 
PARP-2 depletion induces SIRT1 and 
consequently enhance mitochondrial 
biogenesis in skeletal muscle and liver. 
PARP-2 knockout mice; Luciferase 
reporter system in PARP-2 specific 
shRNS treated HEK293T cells; PARP-2 
knockdown C2C12 cells. 
Skeletal muscle, liver [58, 83] 
TTF1 Transcriptional 
cofactor 
Regulates the expression of surfactant 
protein B. 
Luciferase reporter system in PARP-2 
specific shRNS treated HeLa/MLE15 
cells, interaction mapping in mice and in 
cells. 
Lungs [60] 
 
Table
